New Pancreatic Cancer Vaccine Sparked Immune Responses in 99% of Patients

Key Points:

• A phase 2 clinical trial led by the Mayo Clinic tested a novel vaccine, camupepimut, targeting KRAS gene mutations found in about 90% of pancreatic ductal adenocarcinomas, aiming to stimulate an immune response against cancer cells.
• Nearly all patients (98.9%) who received the vaccine developed increased T-cell responses against mutated KRAS, with over 80% showing a more than ninefold increase, indicating the vaccine effectively teaches the immune system to recognize these mutations.
• Despite strong immune responses, there was no statistically significant difference in disease-free survival between vaccinated patients and controls, leaving the clinical benefits of the vaccine unclear at this stage.
• Researchers plan a phase 3 trial to test additional vaccine boosters and combinations with other cancer treatments, following promising results from similar mRNA cancer vaccines in melanoma that have demonstrated improved survival outcomes.
• The development of personalized mRNA vaccines for pancreatic cancer is ongoing, with early clinical trials showing some patients mounting effective immune responses and surviving years post-treatment, signaling a hopeful future for cancer immunotherapy.